	Application No.	Applicant(s)
Notice of Allowability	09/380,086	PEREZ ET AL.
	Examiner	Art Unit
	Anne R. Kubelik	1638
The MAILING DATE of this communication appears on the cover sheet with the correspondence address— All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.  1. This communication is responsive to response and mendment filed 4/14/06.		
2. X The allowed claim(s) is/are 29 and 37-42.		
<ul> <li>3.</li></ul>		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		1
Attachment(s)		
1. Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	<ol> <li>Interview Summary Paper No./Mail Dat</li> </ol>	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date		
4.   Examiner's Comment Regarding Requirement for Deposit	8.   Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.  Other	

## Examiner's Amendment

1. An extension of time under 37 CFR 1.136(a) is required in order to make an examiner's amendment that places this application in condition for allowance. During a telephone conversation conducted on 11 May 2006, Philip DuBois requested an extension of time for 1 MONTH(S) and authorized the Commissioner to charge Deposit Account No. 25-0120 the required fee of \$120.00 for this extension and authorized the following examiner's amendment. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

## IN THE CLAIMS:

In claim 29, line 14, "combined with" was replaced with --each operatively linked to--.

In claims 37 and 41, line 2, "for the" was deleted.

Claim 38. (currently amended) The method according to claim 29, wherein said promoter operably linked to the nucleic acid conferring male sterility is an anther-specific promoter.

In claim 39, line 2, "37" was replaced with --38--.

In claim 40, line 7, "do" was replaced with --dog--.

Art Unit: 1638

## IN THE ABSTRACT:

The invention relates to novel uses of male sterility for improving the conditions for cultivating transgenic plants on behalf of man and the environment a method for preventing the spread via pollen of a transgene encoding dog gastric lipase or collagen from transgenic plants comprising said transgene. In this method plants are transformed with a construct comprising the transgene genetically linked to a second construct conferring male sterility on the plant. Plants produced by the method are male sterile, and thus cannot spread the transgene via their pollen.

## IN THE TITLE:

NOVEL USES USE OF MALE STERILITY TO PREVENT TRANSGENE SPREAD IN PLANTS

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.

The central fax number for official correspondence is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within

Art Unit: 1638

5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Anne R. Kubelik, Ph.D. May 11, 2006

ANNE KUBELIK, PH.D